English  |  正體中文  |  简体中文  |  总笔数 :0  
造访人次 :  51806741    在线人数 :  1005
教育部委托研究计画      计画执行:国立台湾大学图书馆
 
臺灣學術機構典藏系統 (Taiwan Academic Institutional Repository, TAIR)
关于TAIR

浏览

消息

著作权

相关连结

"whang peng j"的相关文件

回到依作者浏览
依题名排序 依日期排序

显示项目 21-30 / 215 (共22页)
<< < 1 2 3 4 5 6 7 8 9 10 > >>
每页显示[10|25|50]项目

机构 日期 题名 作者
臺大學術典藏 2021-09-01T01:54:14Z Clinical Development and Future Direction for the Treatment of Hepatocellular Carcinoma Whang-Peng J.; ANN-LII CHENG; Hsu C.; Chen C.-M.
臺大學術典藏 2021-09-01T01:54:08Z A phase II and pharmacokinetic study of first line S-1 for advanced gastric cancer in Taiwan Chen J.-S.; Chao Y.; Hsieh R.-K.; ANN-LII CHENG; Chen P.-M.; Chiou T.-J.; Chao T.-Y.; Yeh K.-H.; Chen L.-T.; Whang-Peng J.
臺大學術典藏 2021-09-01T01:54:05Z Induction chemotherapy with gemcitabine, oxaliplatin, and 5-fluorouracil/leucovorin followed by concomitant chemoradiotherapy in patients with locally advanced pancreatic cancer: A Taiwan cooperative oncology group phase II study Ch'Ang H.-J.; Lin Y.-L.; Wang H.-P.; Chiu Y.-F.; Chang M.-C.; Hsu C.-H.; Tien Y.-W.; Chen J.-S.; Hsieh R.-K.; Lin P.-W.; Shan Y.-S.; ANN-LII CHENG; Chang J.-Y.; Whang-Peng J.; Hwang T.-L.; Chen L.-T.
臺大學術典藏 2021-09-01T01:53:54Z The aurora kinases inhibitor VE-465 is a novel treatment for glioblastoma multiforme Lee P.-Y.; Chen C.-L.; Lin Z.-Z.; ANN-LII CHENG; Chen E.I.-T.; Whang-Peng J.; Huang C.-Y.F.
臺大學術典藏 2021-08-31T06:29:42Z A phase i clinical study of immunotherapy for advanced colorectal cancers using carcinoembryonic antigen-pulsed dendritic cells mixed with tetanus toxoid and subsequent IL-2 treatment John T Kung Liu K.-J.; Chao T.-Y.; Chang J.-Y.; ANN-LII CHENG; Ch'Ang H.-J.; Kao W.-Y.; Wu Y.-C.; Yu W.-L.; Chung T.-R.; Whang-Peng J.
臺大學術典藏 2021-08-11T03:46:44Z The aurora kinases inhibitor VE-465 is a novel treatment for glioblastoma multiforme Lee P.-Y.; Chen C.-L.; ZHONG-ZHE LIN; Cheng A.-L.; Chen E.I.-T.; Whang-Peng J.; Huang C.-Y.F.
臺大學術典藏 2021-07-03T03:35:40Z Steroid-free chemotherapy decreases risk of hepatitis B virus (HBV) reactivation in HBV-carriers with lymphoma Cheng A.-L.; Hsiung C.A.; Su I.-J.; PEI-JER CHEN; Chang M.-C.; Tsao C.-J.; Kao W.-Y.; Uen W.-C.; Hsu C.-H.; Tien H.-F.; Chao T.-Y.; Chen L.-T.; Whang-Peng J.
臺大學術典藏 2021-07-03T03:35:21Z Long-term hepatic consequences of chemotherapy-related HBV reactivation in lymphoma patients Su W.-P.; Wen C.-C.; Hsiung C.A.; Su I.-J.; Cheng A.-L.; Chang M.-C.; Tsao C.-J.; Kao W.-Y.; Uen W.-C.; Hsu C.-H.; Lu Y.-S.; Tien H.-F.; Chao T.-Y.; Chen L.-T.; Whang-Peng J.; PEI-JER CHEN
臺大學術典藏 2021-07-03T03:35:20Z Phase I and pharmacokinetic study of oral thalidomide in patients with advanced hepatocellular carcinoma Shiah H.-S.; Chao Y.; Chen L.-T.; Yao T.-J.; Huang J.-D.; Chang J.-Y.; PEI-JER CHEN; Chuang T.-R.; Chin Y.-H.; Whang-Peng J.; Liu T.-W.
臺大學術典藏 2021-07-03T03:34:30Z Long-term results of a randomized, observation-controlled, phase III Trial of Adjuvant Interferon alfa-2b in hepatocellular carcinoma after curative resection Chen L.-T.; Chen M.-F.; Li L.-A.; Lee P.-H.; Jeng L.-B.; Lin D.-Y.; Wu C.-C.; Mok K.-T.; Chen C.-L.; Lee W.-C.; Chau G.-Y.; Chen Y.-S.; Lui W.-Y.; Hsiao C.-F.; Whang-Peng J.; PEI-JER CHEN

显示项目 21-30 / 215 (共22页)
<< < 1 2 3 4 5 6 7 8 9 10 > >>
每页显示[10|25|50]项目